CAMBRIDGE, Mass., July 11,
2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a
clinical-stage biopharmaceutical company focused on
creating precisely targeted therapies for
clinically proven kinase targets in cancer, today announced that
Henry Pelish, Ph.D., has been
promoted to Chief Scientific Officer. In this role, Dr. Pelish will
continue to oversee discovery and early-stage development
activities.
"This promotion reflects Henry's significant contributions to
establishing the cornerstone of our approach at Nuvalent:
leveraging a deep expertise in chemistry and structure-based drug
design with the goal to deliver meaningful patient impact," said
James Porter, Ph.D., Chief Executive
Officer at Nuvalent. "Under Henry's leadership, our discovery team
has brought forward three novel kinase inhibitors with the aim of
delivering on potential best-in-class target product profiles, two
of which have demonstrated preliminary clinical proof-of-concept,
and continues to advance a robust discovery pipeline. We are
pleased to recognize his talent, vision, and dedication towards
advancing our mission to discover, develop, and deliver a pipeline
of precisely targeted therapies for patients with cancer."
Dr. Pelish contributed to the creation of Nuvalent and joined as
Biology lead in 2018, overseeing the discovery and early-stage
development of zidesamtinib, NVL-655 and NVL-330 and ongoing
research and discovery efforts. Dr. Pelish earned his Ph.D. in
chemistry from Harvard University and
has over 15 years of experience in cancer biology, chemical biology
and organic chemistry.
"The opportunity to take part in building Nuvalent from the
ground up has been one of the most rewarding experiences of my
career," said Dr. Pelish. "From the outset, our efforts have
focused on solving for the limitations of existing therapies, and I
am encouraged by all we have been able to achieve thus far. I look
forward to continuing to work with my highly dedicated colleagues
towards our goal of delivering tangible benefits to patients with
cancer."
About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a
clinical-stage biopharmaceutical company focused on creating
precisely targeted therapies for patients with cancer,
designed to overcome the limitations of existing therapies for
clinically proven kinase targets. Leveraging deep expertise in
chemistry and structure-based drug design, we develop innovative
small molecules that have the potential to overcome resistance,
minimize adverse events, address brain metastases, and drive more
durable responses. Nuvalent is advancing a robust pipeline with
investigational candidates for ROS1-positive, ALK-positive, and
HER2-altered non-small cell lung cancer, and multiple
discovery-stage research programs.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding Nuvalent's strategy, business plans,
and focus; the potential benefits and effects of Nuvalent's product
development candidates; the potential of Nuvalent's pipeline
programs, including zidesamtinib, NVL-655 and NVL-330; the
implications of data readouts and presentations; Nuvalent's
research and development programs for the treatment of cancer; and
risks and uncertainties associated with drug development. The words
"may," "might," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "aim," "goal," "intend," "believe," "expect,"
"estimate," "seek," "predict," "future," "project," "potential,"
"continue," "target" or the negative of these terms and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Drug development and commercialization
involve a high degree of risk, and only a small number of research
and development programs result in commercialization of a product.
You should not place undue reliance on these statements or the
scientific data presented.
Any forward-looking statements in this press release are based
on management's current expectations and beliefs and are subject to
a number of risks, uncertainties, and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including, without limitation: risks that
Nuvalent may not fully enroll the ARROS-1 or ALKOVE-1 trials or
that enrollment will take longer than expected; unexpected concerns
that may arise from additional data, analysis, or results obtained
during preclinical studies or clinical trials; the risk that
results of earlier clinical trials may not be predictive of the
results of later-stage clinical trials; the risk that data from our
clinical trials may not be sufficient to support registration and
that Nuvalent may be required to conduct one or more additional
studies or trials prior to seeking registration of our product
candidates; risks that Nuvalent may not achieve the goals and
milestones set forth in its OnTarget 2026 operating plan; the
occurrence of adverse safety events; risks that the FDA may not
approve our potential products on the timelines we expect, or at
all; risks of unexpected costs, delays, or other unexpected
hurdles; risks that Nuvalent may not be able to nominate drug
candidates from its discovery programs; the direct or indirect
impact of public health emergencies or global geopolitical
circumstances on the timing and anticipated timing and results of
Nuvalent's clinical trials, strategy, and future operations,
including the ARROS-1 and ALKOVE-1 trials; the timing and outcome
of Nuvalent's planned interactions with regulatory authorities; and
risks related to obtaining, maintaining, and protecting Nuvalent's
intellectual property. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Nuvalent's Quarterly Report on Form 10-Q for the quarterly
period ended March 31, 2024, as well
as any prior and subsequent filings with the Securities and
Exchange Commission. In addition, any forward-looking statements
represent Nuvalent's views only as of today and should not be
relied upon as representing its views as of any subsequent date.
Nuvalent explicitly disclaims any obligation to update any
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvalent-announces-promotion-of-henry-pelish-phd-to-chief-scientific-officer-302194176.html
SOURCE Nuvalent, Inc.